FI963779L - MAGE-kasvainhyljintäantigeeniprekursoreista saatuja eristettyjä peptidejä, jotka kompleksoituvat HLA-A2-molekyylien kanssa - Google Patents

MAGE-kasvainhyljintäantigeeniprekursoreista saatuja eristettyjä peptidejä, jotka kompleksoituvat HLA-A2-molekyylien kanssa Download PDF

Info

Publication number
FI963779L
FI963779L FI963779A FI963779A FI963779L FI 963779 L FI963779 L FI 963779L FI 963779 A FI963779 A FI 963779A FI 963779 A FI963779 A FI 963779A FI 963779 L FI963779 L FI 963779L
Authority
FI
Finland
Prior art keywords
hla
molecules
complex
peptides derived
isolated peptides
Prior art date
Application number
FI963779A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI963779A7 (fi
FI963779A0 (fi
Inventor
Alan Townsend
Judy Bastin
Thierry Boon-Falleur
Der Bruggen Pierre Van
Pierre Coulie
Thomas Gajewski
Cornelis J M Melief
M W Visseren
W M Kast
Original Assignee
Ludwig Inst Cancer Res
Cancellor Masters And Scholars
Univ Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/217,186 external-priority patent/US5585461A/en
Application filed by Ludwig Inst Cancer Res, Cancellor Masters And Scholars, Univ Leiden filed Critical Ludwig Inst Cancer Res
Publication of FI963779A7 publication Critical patent/FI963779A7/fi
Publication of FI963779A0 publication Critical patent/FI963779A0/fi
Publication of FI963779L publication Critical patent/FI963779L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI963779A 1994-03-24 1995-03-22 MAGE-kasvainhyljintäantigeeniprekursoreista saatuja eristettyjä peptidejä, jotka kompleksoituvat HLA-A2-molekyylien kanssa FI963779L (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/217,186 US5585461A (en) 1994-03-24 1994-03-24 Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US08/261,160 US5591430A (en) 1994-03-24 1994-06-17 Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US08/290,381 US5851523A (en) 1994-03-24 1994-08-15 Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
PCT/US1995/003657 WO1995025740A1 (en) 1994-03-24 1995-03-22 Isolated peptides derived from mage tumor rejection antigen precursors which complex with hla-a2 molecules

Publications (3)

Publication Number Publication Date
FI963779A7 FI963779A7 (fi) 1996-09-23
FI963779A0 FI963779A0 (fi) 1996-09-23
FI963779L true FI963779L (fi) 1996-09-23

Family

ID=27396385

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963779A FI963779L (fi) 1994-03-24 1995-03-22 MAGE-kasvainhyljintäantigeeniprekursoreista saatuja eristettyjä peptidejä, jotka kompleksoituvat HLA-A2-molekyylien kanssa

Country Status (16)

Country Link
US (1) US5851523A (da)
EP (2) EP0804483B1 (da)
JP (1) JP3536179B2 (da)
CN (1) CN1151170C (da)
AT (1) ATE198336T1 (da)
AU (1) AU698781B2 (da)
CA (1) CA2186004C (da)
DE (1) DE69519748T2 (da)
DK (1) DK0804483T3 (da)
ES (1) ES2154728T3 (da)
FI (1) FI963779L (da)
GR (1) GR3035636T3 (da)
NO (1) NO963919L (da)
NZ (1) NZ283587A (da)
PT (1) PT804483E (da)
WO (1) WO1995025740A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723832B1 (en) * 1996-10-03 2004-04-20 Ludwig Institute For Cancer Research Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
EP0785274B1 (en) * 1996-01-18 2000-09-27 Aventis Pharma Deutschland GmbH An artifical recombinant substrate (rAGG-1) and native aggrecan to study the proteolytic activity of 'Aggrecanase' in cell culture systems
ATE377022T1 (de) * 1997-06-23 2007-11-15 Ludwig Inst Cancer Res Isolierte decapeptide, die an hla moleküle binden,sowie deren verwendung
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US5965535A (en) 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
GB9826143D0 (en) 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
US7090847B1 (en) * 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
EP1905832A3 (en) * 1999-09-09 2009-09-09 Schering Corporation Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions
AU780163B2 (en) * 1999-09-09 2005-03-03 Merck Sharp & Dohme Corp. Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions
CN1402782A (zh) * 1999-10-19 2003-03-12 路德维哥癌症研究院 Mage－a12抗原肽及其应用
US6897288B1 (en) 1999-10-19 2005-05-24 Ludwig Institute For Cancer Research Mage-A12 antigenic peptides and uses thereof
DK1282702T3 (da) 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
ES2290449T3 (es) 2002-04-09 2008-02-16 Sanofi Pasteur Limited Acido nucleico de cea modificado y vectores de expresion.
EP1556082A1 (en) * 2002-10-22 2005-07-27 Aventis Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
CA2550583C (en) * 2003-10-08 2013-01-15 Sanofi Pasteur, Inc. Modified cea /b7 vector
KR20100061480A (ko) * 2007-09-11 2010-06-07 몬도바이오테크 래보래토리즈 아게 치료제로서의 글루카곤（１－２９） 단독 또는 뉴로펩티드 ｗ３０과의 배합물의 용도
CN106117334B (zh) * 2016-06-24 2020-02-11 秦皇岛未名健康城开发有限公司 一种肿瘤抗原mage3的ctl识别表位肽及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
WO1994003205A1 (en) * 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
US5519117A (en) * 1992-12-22 1996-05-21 Ludwig Institute For Cancer Research Isolated, tyrosinase derived peptides and uses thereof
BR9406652A (pt) * 1993-03-05 1996-09-10 Cytel Corp Composição

Also Published As

Publication number Publication date
DK0804483T3 (da) 2001-02-12
EP0960622A2 (en) 1999-12-01
JP3536179B2 (ja) 2004-06-07
ATE198336T1 (de) 2001-01-15
ES2154728T3 (es) 2001-04-16
AU698781B2 (en) 1998-11-05
CN1151170C (zh) 2004-05-26
NO963919D0 (no) 1996-09-19
AU2192895A (en) 1995-10-09
FI963779A7 (fi) 1996-09-23
WO1995025740A1 (en) 1995-09-28
CA2186004A1 (en) 1995-09-28
PT804483E (pt) 2001-06-29
DE69519748D1 (de) 2001-02-01
CA2186004C (en) 2008-09-23
CN1150805A (zh) 1997-05-28
NO963919L (no) 1996-11-20
EP0804483B1 (en) 2000-12-27
NZ283587A (en) 1998-04-27
JPH10504518A (ja) 1998-05-06
FI963779A0 (fi) 1996-09-23
GR3035636T3 (en) 2001-06-29
EP0960622A3 (en) 1999-12-22
US5851523A (en) 1998-12-22
EP0804483A4 (en) 1998-05-20
DE69519748T2 (de) 2001-10-18
EP0804483A1 (en) 1997-11-05

Similar Documents

Publication Publication Date Title
FI963779L (fi) MAGE-kasvainhyljintäantigeeniprekursoreista saatuja eristettyjä peptidejä, jotka kompleksoituvat HLA-A2-molekyylien kanssa
ZA952374B (en) Isolated peptides derived from MAGE antigen precursors which complex with HLA-A2 molecules and uses thereof
FI963780L (fi) Kasvainhyljintäantigeeniprekursorista MAGE-2 saatuja eristettyjä peptidejä ja niiden käyttöjä
NO902744L (no) Forbedret haarkondisjoneringshampo.
PT1093381E (pt) Peptidos antigenicos derivados de telomerase
FI963033L (fi) Tuumorirejektioantigeenin esiasteeseen MAGE-1 sitoutuvia monoklonaalisia vasta-aineita, rekombinantti-MAGE-1 ja MAGE-1-peräisiä immunogeenisia peptidejä
EP0594436A3 (en) Spring for tissue retention.
DE69433406T2 (de) Antikörper gegen cd40
FI963781A7 (fi) Eristettyjä, MAGE-3-peräisiä peptidejä, jotka kompleksoivat HLA-A2-mol ekyylejä, ja niiden käyttöjä
FI905003L (fi) Glykosaminoglykan modifierat protein.
DE69534325D1 (de) Peptide zur behandlung von krebs
NO910200D0 (no) Fremgangsmaate for fremstilling av polypeptider.
NZ331398A (en) Tumor rejection antigens presented by hla-b44 molecules, and uses thereof
WO2001029220A3 (en) Mage-a12 antigenic peptides and uses thereof
FI912344A0 (fi) Kompressionsskarv foer glasoegon.
DE59106163D1 (de) Mittel zur festigung der haare.
FI970071A0 (fi) Eristetty nukleiinihapposekvenssi, joka koodaa HLA-A2:n esittämää tuumorihyljintäantigeeniä
NO904898D0 (no) Baaren filtreringsmembran og fremgangsmaate for fremstilling av denne.
FI921582L (fi) Fibronektin-bindningsprotein.
NO901129D0 (no) Fremgangsmaate ved fremstilling av sdk-peptider.
GB9721432D0 (en) Improved production of antibodies through the use of antigen antibody complexes
ES1034081Y (es) Portamechas para expositores de peluqueria.
NZ320837A (en) Peptides derived from tumor rejection antigen precursors and presented by hla-b44 useful in diagnostic and therapeutic methodologies
FI963615L (fi) Peptidit, jotka estävät pepsiinin vapautumisen
ES1015557Y (es) Parasol para vehiculos.